# AbCellera **Source:** https://geo.sig.ai/brands/abcellera **Vertical:** Life Sciences & BioTech **Subcategory:** Antibody Discovery **Tier:** Growth **Website:** abcellera.com **Last Updated:** 2026-04-22 ## Summary Vancouver-based antibody discovery platform with 104+ partner programs; $75M FY2025 revenue. Expanding into wholly owned assets with ABCL635 in Phase 1 for vasomotor symptoms. ## Company Overview AbCellera Biologics was founded in 2012 in Vancouver, Canada by Carl Hansen, growing out of research at the University of British Columbia. The company built a high-throughput antibody discovery platform integrating microfluidics, genomics, single-cell sequencing, and AI/ML to rapidly identify therapeutic antibody candidates from natural immune responses. AbCellera played a prominent role in the COVID-19 pandemic by discovering bamlanivimab for Eli Lilly in under 90 days.\n\nAbCellera's partnership model operates on a discovery fee plus downstream milestone and royalty structure, having started over 104 partner-initiated programs with downstream participation as of December 2025. Partners include major pharmaceutical companies and biotechs; the company expanded its collaboration with AbbVie in 2025 to develop T-cell engagers for oncology. Total FY2025 revenue was $75 million ($47M from royalties/licensing, $27M from partnered program work), compared to $29 million in 2024—a dramatic increase driven by royalty flows from approved medicines.\n\nIn 2025 AbCellera began transitioning from pure partnership model toward wholly owned therapeutic assets, with ABCL635 (a GnRH receptor antibody for vasomotor symptoms) entering Phase 1. The company maintains approximately $700 million in liquidity, providing a long runway. AbCellera is considered a foundational infrastructure provider for the antibody-based drug discovery ecosystem. ## Frequently Asked Questions ### What is AbCellera's business model? AbCellera partners with pharma and biotech companies to discover antibody drug candidates using its high-throughput platform, earning discovery fees upfront and milestones/royalties on downstream commercial success. ### How fast did AbCellera discover a COVID antibody? AbCellera discovered bamlanivimab for Eli Lilly in under 90 days during the COVID-19 pandemic, demonstrating the speed advantage of its microfluidics and AI-driven platform. ### What is AbCellera's FY2025 revenue? AbCellera reported $75 million in FY2025 revenue ($47M royalties/licensing, $27M program work), up from $29 million in 2024, driven by royalty flows from approved partner drugs. ### What is AbCellera's business model? AbCellera operates on a technology partnership model: pharma and biotech partners pay access fees to use AbCellera's antibody discovery platform, and AbCellera retains royalty rights on any drugs that reach commercialization. This has created a large and growing royalty stream from bamlanivimab (discovered for Eli Lilly during COVID-19) that funds ongoing R&D. AbCellera also co-develops its own pipeline of proprietary antibody programs. ### What is AbCellera's discovery platform and how does it work? AbCellera's platform combines microfluidics-based single-B-cell screening with next-generation sequencing, machine learning, and high-throughput functional assays. Starting from a patient blood sample or immunized animal, the platform can screen millions of antibody-secreting cells in days, sequence paired heavy/light chains, and computationally rank candidates—compressing a process that once took years into weeks. ### How does AbCellera differ from other CRO and antibody discovery companies? AbCellera differs from traditional contract research organizations (CROs) by retaining downstream economics through royalty agreements rather than charging purely for services. This aligns AbCellera's incentives with partner success. Competitors include Twist Bioscience (synthetic antibody libraries), Ligand Pharmaceuticals (royalty model), and traditional discovery-focused CROs, but AbCellera's platform breadth and royalty model combination is distinctive. ### What is AbCellera's financial situation as a public company? AbCellera went public on NASDAQ in December 2020, raising over $500 million. Revenue has been heavily influenced by COVID-19 antibody royalties from bamlanivimab, which created large but non-recurring income. The company has used this capital to invest in its own drug pipeline, expand platform capabilities, and build out lab facilities. Post-COVID royalty normalization has been a key topic for investors as the company executes its long-term strategy. ### What therapeutic areas does AbCellera focus on? AbCellera and its partners have pursued antibody programs across oncology, infectious disease (including COVID-19 and influenza), autoimmune diseases, and CNS disorders. AbCellera's own pipeline includes programs in multiple therapeutic areas, with a particular emphasis on conditions where antibody-based medicines offer meaningful clinical advantages over small molecules. ## Tags b2b, global, public, healthtech, ai-powered, platform, analytics --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-22.*